New blood tests can detect cancer recurrence earlier than traditional scans, potentially giving doctors and patients crucial ...

The number of lung cancer cases in people who have never smoked is increasing. The disease is different from lung cancer ...

Survival outcomes favored the higher dose: more than 93% of patients in the 70 Gy group were alive one year after treatment, ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The Phase III IMforte study shows that adding lurbinectedin to Tecentriq for ES-SCLC first-line maintenance reduced disease ...

Prof Patrick Forde of the Trinity St James’s Cancer Institute presented the findings at the latest meeting of the American ...

CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with ...

After years of lobbying from patients, the first ever national lung cancer screening program will roll out next month for ...

CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response ...